The perioperative safety of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei
10.3760/cma.j.cn112152-112152-20190430-00278
- VernacularTitle:肿瘤细胞减灭术联合腹腔热灌注化疗治疗腹膜假黏液瘤的围手术期安全性研究
- Author:
Xinbao LI
1
;
Ru MA
;
Zhonghe JI
;
Yulin LIN
;
Jue ZHANG
;
Zhiran YANG
;
Linfeng CHEN
;
Fengcai YAN
;
Yan LI
Author Information
1. 首都医科大学附属北京世纪坛医院腹膜肿瘤外科100038
- Keywords:
Pseudomyxoma peritonei;
Cytoreductive surgery;
Hyperthermic intraperitoneal chemotherapy;
Serious adverse events
- From:
Chinese Journal of Oncology
2020;42(5):419-424
- CountryChina
- Language:Chinese
-
Abstract:
Objective:This study was to investigate the perioperative safety of cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) for pseudomyxoma peritonei (PMP), and analyze the risk factors of serious adverse events (SAEs).Methods:The occurrences of perioperative SAEs were retrospectively analyzed in 254 PMP patients treated with CRS plus HIPEC. Univariate and multivariate analysis were performed to identify independent risk factors.Results:Among the 272 CRS plus HIPEC procedures for 254 PMP patients, a total of 93 (34.2%) perioperative SAEs occurred, including 26 in infection, 22 in digestive system, 17 in respiratory system, 15 in cardiovascular system, 8 in hematological system, and 4 in urinary system. In terms of severity, the vast majority was grade Ⅲ with 76 cases, followed by grade Ⅳ with 13 cases and grade Ⅴ with 4 cases. Univariate analysis revealed 3 risk factors of perioperative SAEs: HIPEC regimen ( P=0.020), intraoperative red blood cell transfusion volume ( P=0.004), and intraoperative blood loss volume ( P=0.002). Multivariate analysis by logistic regression model analysis revealed that intraoperative red blood cell transfusion volume was an independent risk factor for perioperative SAEs ( OR=1.160, P=0.001). Conclusion:In conclusion, the perioperative safety of CRS plus HIPEC was acceptable. Moreover, intraoperative blood loss volume and red blood cell transfusion volume are expected to be reduced in order to prevent SAEs for PMP patients.
